PDCD1 and non-small cell lung carcinoma: More recently, other ICI monotherapies have been added to the available first-line treatments in Europe, atezolizumab (anti-PD-L1) in patients with PD-L1 expression ≥50% on tumor cells (Impower110 trial) [9,10], and cemiplimab (anti-PD-1) in those with PD-L1 expression ≤50% (Empower-lung 1 trial) [11] The improved efficacy in terms of OS of immunotherapy plus doublet CT over the single ICI treatment was reported in both squamous (KEYNOTE-407 and IMpower131) and non-squamous (Keynote-189, IMpower 150, IMpower 130, and IMpower132) NSCLC [12,13,14,15,16,17].